The House Energy & Commerce Health Subcommittee on Health hearing entitled, “Examining the 340B Drug Pricing Program”, originally scheduled for Thursday, March 5th has been RESCHEDULED for March 24, 2015 at 10:00 a.m. EST.
The purpose of the hearing will be to review the functionality of the program to understand how it impacts patients, providers, manufacturers, and other stakeholders. The event will be available via webcast here.
Overview
This webcast offers the health care provider community and other 340B stakeholders a unique opportunity to hear the specific compliance issues and concerns that Congress has with the program, as well as the opinions and responses of those government agencies that have been administering and examining the 340B Program in recent years. Witnesses at the hearing include Diana Espinosa, Deputy Administrator of Health Resources and Services Administration, accompanied by CDR Krista M. Pedley, Director of the Office of Pharmacy Affairs; Debbie Draper, Director, Health Care, of the Government Accountability Office; and Anne Maxwell, Assistant Inspector General for Evaluation and Inspections, Office of Inspector General.
Additional Information
In anticipation of the Tuesday hearing, the House Energy & Commerce Health Subcommittee has released a background memo as well as some written testimony. The memo offers additional detail on the 340B Program and outlines some key issues that the 340B Program is encountering. The memo and testimony can be found here.
Members of Polsinelli’s Public Policy team will be present at the hearing, but we encourage all 340B stakeholders to take advantage of this rare opportunity to listen in on testimony from key 340B Program representatives. Polsinelli will also provide a summary of the hearing and any submitted written witness testimony in the days following the hearing.
